The Latest Breaking News from MHRA

Mounjaro will come in a four-dose device known as a KwikPen for people with type 2 diabetes or obesity

Exclusive: Crizanlizumab was hailed as first new drug to be introduced in over 20 years for people living with sickle cell disease

The MHRA has launched a new regulatory roadmap that will help make future regulations for UK medical devices keeping in mind patient safety and their ability to harness medical technology advancements.

Clozapine is said to be prescribed for around 37,000 Brits a year but can cause toxicity

The Rosalind Franklin Laboratory – which has received more than £1 billion of public funding – is currently on sale on Rightmove.

Veoza distinguishes itself as a non-hormonal menopause drug that directly targets the brain to prevent hot flushes.

Veoza is the new drug for hot flushes that's been approved for use in the UK with immediate effect

Two geneticists explain the groundbreaking CRISPR-based therapies approved for sickle-cell disease and β-thalassaemia, and other genetic therapeutics in development, including base-editing and prime-editing.

Given enhanced healthcare spending, the growing frequency of chronic diseases, government support, and rapid digital transformation, the biotech industry appears to have favorable prospects. Therefore, fundamentally strong biotech stocks Vertex Pharmaceuticals (VRTX), Innoviva (INVA), and Acorda Therapeutics, Inc. (ACOR) could be ideal additions to your portfolio this week. Read more….

U.K. regulators have approved the use of a CRISPR therapy called Casgevy to treat two inherited blood disorders. But what is it and how does it work?

Using the gene editing tool CRISPR, the new therapy promises a cure for those with sickle cell anemia and beta thalassemia, but cost could be a barrier to care.